Literature DB >> 26765522

Do stones still kill? An analysis of death from stone disease 1999-2013 in England and Wales.

Francesca Kum1, Wasim Mahmalji1, Jemma Hale1, Kay Thomas1, Matthew Bultitude1, Jonathan Glass1.   

Abstract

OBJECTIVES: To analyse the trends in the number of deaths attributable to urolithiasis in England and Wales over the past 15 years (1999-2013). Urolithiasis has an estimated lifetime risk of 12% in males and 6% in females and is not perceived as a life-threatening pathology. Admissions with urinary calculi contribute to 0.5% of all inpatient hospital stays, and the number of deaths attributable to stone disease has yet to be identified and presented.
MATERIALS AND METHODS: Office of National Statistics data relating to causes of death from urolithiasis, coded as International Classification of Diseases (ICD)-10 N20-N23, was collated and analysed for the 15-year period from 1999 to 2013 in England and Wales. These data were sub-categorised into anatomical location of calculi, age, and gender.
RESULTS: In all, 1954 deaths were attributed to urolithiasis from 1999 to 2013 (mean 130.3 deaths/year). Of which, 141 were attributed to ureteric stones (mean 9.4 deaths/year). Calculi of the kidney and ureter accounted for 91% of all deaths secondary to urolithiasis; lower urinary tract (bladder or urethra) calculi contributed to only 7.9% of deaths. The data revealed an overall increasing trend in mortality from urolithiasis over this 15-year period, with an increase of 3.8 deaths/year based on a linear trend (R(2) = 0.65). Overall, the number of deaths in females was significantly higher than in males (ratio 1.5:1, P < 0.001); kidney and ureteric calculi causing death had a female preponderance (1.7:1, female:male); whereas calculi of the lower urinary tract was more common in males (1:2.2, female:male).
CONCLUSIONS: Stone disease still causes death in the 21st century in England and Wales. This trend of increasing deaths must be placed in the context of the concurrent rising incidence of urolithiasis in the UK and the number of stone-related hospital episodes. The primary cause of death relating to complications of stone disease for each individual case should be further investigated to facilitate prevention of complications of urolithiasis.
© 2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  epidemiology; mortality; sepsis; urinary calculi; urolithiasis

Mesh:

Year:  2016        PMID: 26765522     DOI: 10.1111/bju.13409

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

Review 1.  Stones: The dark side of stone disease - stones do still kill.

Authors:  Marcelino Rivera; Amy Krambeck
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

Review 2.  Updates in the Metabolic Management of Calcium Stones.

Authors:  Kristina L Penniston; Stephen Y Nakada
Journal:  Curr Urol Rep       Date:  2018-04-16       Impact factor: 3.092

3.  Deregulated MTOR (mechanistic target of rapamycin kinase) is responsible for autophagy defects exacerbating kidney stone development.

Authors:  Rei Unno; Tsuyoshi Kawabata; Kazumi Taguchi; Teruaki Sugino; Shuzo Hamamoto; Ryosuke Ando; Atsushi Okada; Kenjiro Kohri; Tamotsu Yoshimori; Takahiro Yasui
Journal:  Autophagy       Date:  2019-06-29       Impact factor: 16.016

4.  Outcome of uncomplicated ureteric calculi managed with medical expulsive therapy in the outpatient clinic of a urology unit in Sri Lanka.

Authors:  Malaka Dharmakeerthi Jayawardene; Balasingam Balagobi; A L A M C Ambegoda; Sanjeewa Vidanapathirana; G W A S K Wijayagunawardane; V Senthan; D D Ranasinghe; Anuruddha M Abeygunasekera
Journal:  BMC Res Notes       Date:  2017-11-28

5.  Successful ureteroscopy for kidney stone disease leads to resolution of urinary tract infections: Prospective outcomes with a 12-month follow-up.

Authors:  Rachel Oliver; Anngona Ghosh; Robert Geraghty; Sacha Moore; Bhaskar K Somani
Journal:  Cent European J Urol       Date:  2017-11-07

6.  Low bone mineral density is a potential risk factor for symptom onset and related with hypocitraturia in urolithiasis patients: a single-center retrospective cohort study.

Authors:  Kazumi Taguchi; Shuzo Hamamoto; Atsushi Okada; Yutaro Tanaka; Teruaki Sugino; Rei Unno; Taiki Kato; Ryosuke Ando; Keiichi Tozawa; Takahiro Yasui
Journal:  BMC Urol       Date:  2020-10-29       Impact factor: 2.264

7.  HydroZitLa inhibits calcium oxalate stone formation in nephrolithic rats and promotes longevity in nematode Caenorhabditis elegans.

Authors:  Nalinthip Lordumrongkiat; Nattida Chotechuang; Mani Iyer Prasanth; Depicha Jindatip; Chakriwong Ma-On; Kamonchanok Chuenwisad; Asada Leelahavanichkul; Tewin Tencomnao; Chanchai Boonla
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.